Tarsus Pharmaceuticals (TARS) Common Equity (2019 - 2026)

Tarsus Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $349.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 1.9% year-over-year to $349.0 million in Q1 2026; TTM through Mar 2026 was $349.0 million, a 1.9% increase from a year earlier, with the FY2025 full-year figure at $343.4 million, up 52.95% from the prior year.
• Common Equity grew to $349.0 million in Q1 2026 per TARS's latest filing, from $343.4 million in the prior quarter.
• Across five years, Common Equity topped out at $349.0 million in Q1 2026 and bottomed at $147.7 million in Q2 2023.
• The 5-year median for Common Equity is $224.5 million (2024), against an average of $246.5 million.
• Across the five-year window, Common Equity sank 33.31% in 2023 and surged 70.75% in 2024, its largest moves.
• Year by year, Common Equity stood at $192.9 million in 2022, then advanced by 2.12% to $197.0 million in 2023, then advanced by 13.98% to $224.5 million in 2024, then surged by 52.95% to $343.4 million in 2025, then climbed by 1.61% to $349.0 million in 2026.
• Per Business Quant, the three latest TARS Common Equity figures stand at $349.0 million (Q1 2026), $343.4 million (Q4 2025), and $335.1 million (Q3 2025).